In vivo evidence for nitric oxide-mediated calcium-activated potassium-channel activation during human endotoxemia. by Pickkers, P. et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/51299
 
 
 
Please be advised that this information was generated on 2017-12-06 and may be subject to
change.
In Vivo Evidence for Nitric Oxide–Mediated
Calcium-Activated Potassium-Channel Activation During
Human Endotoxemia
Peter Pickkers, MD, PhD; Mirrin J. Dorresteijn, MSc;
Martijn P.W.J.M. Bouw; Johannes G. van der Hoeven, MD, PhD; Paul Smits, MD, PhD
Background—During septic shock, the vasoconstrictor response to norepinephrine is seriously blunted. Animal
experiments suggest that hyperpolarization of smooth muscle cells by opening of potassium (K) channels underlies this
phenomenon. In the present study, we examined whether K-channel blockers and/or nitric oxide (NO) synthase
inhibition could restore norepinephrine sensitivity during experimental human endotoxemia.
Methods and Results—Volunteers received 2 ng/kg Escherichia coli endotoxin intravenously. Forearm blood flow (FBF) was
measured with venous occlusion plethysmography. Infusion of 4 dose steps of norepinephrine into the brachial artery
decreased the FBF ratio (ratio of FBF in the experimental arm to FBF in the control arm) to 844%, 704%, 554%, and
384% (meanSEM) of its baseline value. After endotoxin administration, norepinephrine-induced vasoconstriction was
attenuated (FBF ratio, 1014%, 924%, 836%, and 567%; n30; P0.0018; pooled data). Intrabrachial infusion of the
K-channel blocker tetraethylammonium (TEA) completely restored the vasoconstrictor response to norepinephrine from
1045%, 937%, 9312%, and 6912% to 899%, 734%, 595%, and 468% (n6; P0.045). Other K-channel
blockers did not affect the response to norepinephrine. The NO synthase inhibitor NG-monomethyl-L-arginine (L-NMMA; 0.2
mg · min1 · dL1 intra-arterially) also restored the norepinephrine sensitivity. In the presence of L-NMMA, TEA did not have
an additional effect on the norepinephrine-induced vasoconstriction (n6; P0.9).
Conclusions—The K-channel blocker TEA restores the attenuated vasoconstrictor response to norepinephrine during
experimental human endotoxemia. Coadministration of L-NMMA abolishes this potentiating effect of TEA, suggesting
that NO mediates the endotoxin-induced effect on vascular K channels. In the absence of an effect of the selective
adenosine triphosphate–dependent K-channel blocker tolbutamide, we conclude that the blunting effect of endotoxin on
norepinephrine-induced vasoconstriction is caused by NO-mediated activation of calcium-activated K channels in the
vascular wall. (Circulation. 2006;114:414-421.)
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Sepsis is the most common cause of death among patientsin noncoronary intensive care units, resulting in an
estimated mortality of 6 million patients each year world-
wide.1,2 Vasodilatory shock, defined as hemodynamic insta-
bility resulting from a decreased vascular tone and attenuated
sensitivity to vasopressor therapy, is a characteristic feature
of sepsis and the main cause of its mortality.3
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Increased synthesis of nitric oxide (NO) and activation of
vascular potassium (K) channels4 represent 2 pathways that appear
to play an important role in the dysregulation of vascular tone in
septic patients. Although it has been demonstrated that increased
expression of inducible NO synthase is detectable only at the site of
infection,5 systemic administration of its inhibitor, NG-monometh-
yl-L-arginine (L-NMMA), results in a rise in blood pressure and an
increase in sensitivity to vasopressor drugs.6
Simultaneously, several inflammatory mediators may lead
to activation of vascular K channels. Opening of vascular K
channels hyperpolarizes the membrane of vascular smooth
muscle cells, leading to closure of voltage-operated calcium
channels and vasorelaxation. Moreover, activation of vascu-
lar K channels is associated with an attenuated response to
vasoconstrictors,7 and persistent membrane hyperpolarization
by K-channel activation appears to account for much of the
observed vascular hyporeactivity of septic shock.7,8 Of the
several subtypes of K channels present in the vascular wall,
activation of the calcium-activated (KCa) and adenosine
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triphosphate (ATP)–dependent (KATP) K channels are associ-
ated with inflammation-induced vascular hyporeactivity.
Animal experiments have demonstrated that administration of
K-channel blockers during sepsis results in an increase in blood
pressure, an increase in vasopressor sensitivity, and even a reduction
in mortality.9–12 Interestingly, NO is one of the mediators that
activates the KCa channel during inflammation.9,13,14
Acute systemic inflammation can be induced by a low-
dose infusion of Escherichia coli lipopolysaccharide (LPS) in
healthy volunteers, resulting in changes in cardiovascular
function comparable to those observed in sepsis.15,16 Human
data concerning the role of NO during inflammation are
limited, and no human data are available concerning the role
of vascular K-channel activation.
In the present study, we quantified the effect of LPS
infusion on the vasoconstrictor response to norepinephrine in
the human forearm vasculature in the absence and presence of
K-channel blockade and NO synthase inhibition. The study
addresses 3 questions: Is it possible to restore the vascular
hyporeactivity to norepinephrine during human endotoxemia
by pharmacological K-channel blockade? Which vascular K
channel (KCa or KATP) is involved? And finally, is the
activation of the vascular K channels during human endotox-
emia mediated by NO?
Methods
Subjects
After approval was obtained from our ethics committee, 36 non-
smoking subjects (18 women, 18 men) gave written informed
consent to participate in the experiments. Subjects taking prescrip-
tion drugs (except for oral contraceptives), aspirin, or other nonste-
roidal antiinflammatory drugs were excluded. Screening of the
subjects within 14 days before the test revealed no abnormalities in
medical history and physical examination. Routine laboratory tests
and ECG were normal. All subjects tested negative for HIV and
hepatitis B. Ten hours before the experiment, subjects refrained from
caffeine, alcohol, and food.
Study Design of Human Endotoxemia Experiments
After local anesthesia (lidocaine HCL 20 mg/mL), the brachial artery
was cannulated with a 20-gauge catheter connected to an arterial
pressure monitoring line (Siemens SC9000, Den Haag, The Nether-
lands). The arterial line was used to administer drugs (norepinephrine,
K-channel blockers, L-NMMA), to monitor blood pressure, and to
sample blood.
Heart rate and blood pressure monitoring started 2 hours before
LPS administration and was continued until the end of the experi-
ment. A second cannula was placed in a deep antecubital vein for
prehydration (1.5 L of 2.5% glucose/0.45% saline solution in the
hour before the administration of LPS) and LPS administration. All
subjects received 150 mL/h 2.5% glucose/0.45% saline solution
during the first 6 hours after the LPS administration and 75 mL/h
until the end of the experiment.
At 0 hours, purified endotoxin (LPS) prepared from E coli O:113
was injected (2 ng/kg IV) in 1 minute. LPS in the current dose
attenuates the vasoconstrictor response to adrenergic16 and other
vasoconstrictors.17
The course of body temperature was determined every 30 minutes
for the first 6 hours after LPS administration with an infrared
tympanic thermometer (Sherwood Medical, ’s-Hertogenbosch, the
Netherlands).
Laboratory Tests
Blood samples were taken to determine the time course and peak
values per individual. Total leukocytes and C-reactive protein values
were measured before LPS administration and at 1, 6, 12, and 22
hours after LPS with standard laboratory techniques. To determine
the concentration of the various cytokines, plasma was processed
immediately by centrifugation at 2000g at 4°C for 15 minutes and
was stored at 80°C before analyses. Concentrations of tumor
necrosis factor-, interleukin (IL)-1, IL-6, IL-10, and interferon-
were determined in samples taken at baseline and at 60 and 90
minutes and 2, 3, and 4 hours after LPS administration with
simultaneous Luminex assay.18
Forearm Blood Flow Measurements
Forearm blood flow (FBF) was determined in both forearms with
venous occlusion plethysmography (Filtrass Domed, Munich, Ger-
many) as previously described.19,20 Briefly, venous occlusion was
achieved by inflating the upper arm cuffs to 45 mm Hg. Strain
gauges were placed on the forearms and connected to plethysmo-
graphs to measure changes in forearm volume in response to
inflation of the venous-congesting cuffs. FBF and drug administra-
tion were normalized to forearm volume as measured with the water
displacement method and expressed in milliliters per minute per
deciliter forearm volume (mL · min1 · dL1).
Norepinephrine Dose Response
After instrumentation of both arms and an equilibration period of 30
minutes, the vasoconstrictor response to infusion of norepinephrine
Figure 1. Flow chart of the study proto-
col. The first norepinephrine dose-
response curve represents the baseline
norepinephrine sensitivity. The second (4
hours) includes the effect of LPS on nor-
epinephrine sensitivity; the third (5 hours)
shows the effect of the pharmacological
intervention (placebo, K-channel block-
ers, and/or L-NMMA). HR indicates heart
rate; MAP, mean arterial pressure.
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into the brachial artery was quantified by measuring FBF, as
illustrated in Figure 1. Each dose-response curve started with a
5-minute period of baseline measurements, followed by intra-arterial
norepinephrine infusion at 1 to 3 ng · min1 · dL1 to 10 to 30
ng · min1 · dL1 (5 minutes per dose).
Four hours after LPS administration, the norepinephrine dose-
response curve was repeated to determine the LPS-induced effects on
norepinephrine sensitivity. Thereafter, at 5 hours, without selection
or formal randomization, one of the following protocols was applied.
Protocol 1: Time Control Experiments With
Norepinephrine During Endotoxemia
Time control experiments were carried out in 6 subjects to investi-
gate the repeatability of the vasopressor response to norepinephrine.
To this end, the norepinephrine dose-response curve was repeated
once more at 5 hours with NaCl 0.9% as the “placebo” pharmaco-
logical intervention.
Protocol 2: Effect of Various K-Channel Blockers on
Norepinephrine Sensitivity During Endotoxemia
We used the K-channel blockers quinine, tetraethylammonium
(TEA), and tolbutamide to investigate the role of KCa and KATP
channel activation. Using the perfused forearm technique, we have
previously demonstrated that these blockers inhibit the vasodilator
response to activation of KCa21 and KATP22 channels.
In 3 groups of 6 subjects, the norepinephrine dose-response curve
was repeated at 5 hours during continued intra-arterial infusion of
TEA (1 mg · min1 · dL1), quinine (50 g · min1 · dL1), or the
selective KATP blocker tolbutamide (1 mg · min1 · dL1).
Protocol 3: Effects of NO Synthase Inhibitor L-NMMA
and Coinfusion of K-Channel Blocker TEA on
Norepinephrine Sensitivity During Endotoxemia
To determine whether the effect of TEA was induced through a
direct effect of LPS/cytokines on the vascular K channels or whether
this effect was mediated by NO, we infused the NO synthase
inhibitor L-NMMA (0.2 mg · min1 · dL1) intra-arterially in another
6 subjects at 5 hours. After 5 minutes of infusion, the effects of
L-NMMA on FBF were determined. During continued L-NMMA
infusion, a norepinephrine dose-response curve was determined as
described above.
In this group, the experiment was extended to study the effect of
combining TEA and L-NMMA. After a 30-minute washout period (6
hours), L-NMMA and TEA were coinfused to assess whether there
is an additional effect of K-channel blockade during NO synthase
inhibition.
Protocol 4: Effect of K-Channel Blockers and NO
Inhibition on Norepinephrine Sensitivity in the Absence
of Endotoxemia
To assess the effect of intra-arterial administration of TEA and
L-NMMA on the norepinephrine dose-response curve, 6 experiments
without LPS administration were conducted. Study design was
identical to that of the endotoxemia experiments. Because of the long
half-life of L-NMMA, a crossover design could not be applied;
therefore, L-NMMA always was infused last.
A norepinephrine dose-response curve was determined using the same
method as in the endotoxemia experiments. After 30 minutes, intra-arterial
TEA infusion (1 mg · min1 · dL1) was started, and its effects on FBF were
assessed. During continued TEA infusion, the norepinephrine dose-
response was repeated. After another 30-minute washout period, intra-
arterial L-NMMA infusion (0.2 mg · min1 · dL1) was started. After
determining the FBF response to L-NMMA, we repeated the norepi-
nephrine dose-response curve as described above.
Drugs and Solutions
All solutions were freshly prepared on the day of the experiment.
Endotoxin (US Standard Reference Endotoxin E coli O:113, USP,
Rockville, Md), norepinephrine (1 mg/mL, Centrafarm, Etten-Leur,
the Netherlands), quinine dihydrochloride (300 mg/mL, Dagra
Pharma, Diemen, the Netherlands), tolbutamide (10 mg/mL, Clinical
Pharmacy, Radboud University Nijmegen Medical Centre, Nijme-
gen, the Netherlands), and L-NMMA (100 mg ampoules, Clinalfa,
Laufenflingen, Switzerland) were all dissolved in 0.9% NaCl. On the
day of the experiment, TEA was reconstituted from a sterile powder
(Sigma, St Louis, Mo), diluted in NaCl 0.9% to a concentration of 1
mg/mL, and passed through a 0.22-m Millipore (Millipore, Mil-
ford, Mass) filter.
Data Analysis, Calculations, and Statistics
Measurement of the FBF in the noninfused arm was used as a
contemporaneous time control for the infused arm so that systemic
effects could be observed and vasoactive effects could be expressed
as a quotient of the infused and the noninfused arm. According to the
literature, the FBF ratio is the optimal approach to analyze data from
this kind of research.23 Baseline infused-to-noninfused forearm ratio
was defined at 100%.
The effects of quinine, TEA, tolbutamide, L-NMMA, and coinfu-
sion of L-NMMA and TEA are expressed in absolute FBF
(mL · min1 · dL1). Norepinephrine-induced changes in FBF are
expressed as percent flow change. FBF data are the mean of the
measurements obtained during the last 2 minutes of each infusion
period (steady state).
The mean arterial pressure and heart rate were sampled every 5
minutes throughout the experiments. To determine the systemic effects
of the LPS infusion, the group averages before the start of baseline
measurements and the group averages at 4 hours are expressed.
The primary end point of this study is the effect of pharmacolog-
ical interventions (K-channel blockade and NO inhibition) on nor-
epinephrine-induced vasoconstriction in the human forearm vascu-
lature during systemic inflammation. Using NQuery 6.0 (Statistical
Solutions Ltd, Cork, Ireland), we calculated sample size for a
univariate 1-way repeated-measures ANOVA with constant correla-
tion. The computer program was used with a number of levels of 4
(norepinephrine infusion rates), an estimated standard deviation of
20% with a correlation of 0.5, a desired power of 80%, and an
estimated standard deviation of 10% to 15% of the expected means
of differences. With this approach, sample sizes of 4 to 7 were
needed to demonstrate a difference between the repeated measures
before compared with after intervention. Therefore, we chose to
include 6 individuals in each group. LPS-induced changes in clinical,
inflammatory, and hemodynamic parameters were determined to
demonstrate that the inflammatory stimulus was adequate.
Shapiro-Wilk and Kolmogorov-Smirnov tests indicated a normal
distribution of data. LPS-induced effects (pooled n30) and the
effects of all pharmacological interventions in the forearm were
tested for significance with repeated-measures ANOVA. Paired data
(within subjects, comparison of before and after intervention) were
assessed with the Student t test. All data are expressed as
meanSEM unless otherwise specified. A value of P0.05 was
considered statistically significant.
The authors had full access to the data and take full responsibility
for their integrity. All authors have read and agree to the manuscript
as written.
Results
Baseline Characteristics
Baseline characteristics are presented in Table 1. Apart from a
lower blood pressure at baseline in the subgroup that did not
receive LPS, there were no other imbalances between the groups.
Changes in Clinical, Inflammatory, and
Hemodynamic Parameters
LPS administration induced the expected and transient
flulike symptoms. Body temperature increased from
36.40.1°C to 38.00.1°C at 4 hours (P0.0001,
repeated-measures ANOVA), and white blood cell count
decreased from 5.90.3 to 2.10.1109/L at 1 hour after
LPS administration, after which there was an increase to
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13.40.6 and 13.70.6109/L at 6 and 12 hours, respec-
tively (P0.0001, repeated-measures ANOVA).
C-reactive protein was below the detection limit at base-
line, increasing to 5.61.2 mg/dL at 6 hours, 23.01.8
mg/dL at 12 hours, and 35.12.4 mg/dL at 22 hours after
the injection of LPS (P0.0001, repeated-measures
ANOVA). All plasma cytokine concentrations increased
significantly after the administration of LPS (Figure 2).
The hemodynamic response to LPS is characterized by a
significant decrease in blood pressure, rise in heart rate, and
increase in FBF (Table 2). As illustrated in Figure 3,
intrabrachial infusion of norepinephrine induced a dose-
dependent vasoconstrictor effect that was impaired 4 hours
after the administration of LPS (P0.0018, repeated-
measures ANOVA between dose-response curves; n30).
Protocol 1: Time Control Experiments With
Norepinephrine During Endotoxemia
In this group, FBF was 4.00.8 before and 8.72.4
mL · min1 · dL1 after the administration of LPS. Figure 4A illus-
trates that with no pharmacological intervention the impaired
vasoconstrictor response to norepinephrine is similar at 4 hours and
5 hours (Pnonsignificant [NS], repeated-measures ANOVA),
indicating good repeatability of the impaired norepinephrine dose-
response curve at 5 hours after the administration of LPS.
Protocol 2: Effect of Various K-Channel Blockers on
Norepinephrine Sensitivity During Endotoxemia
In the quinine group, LPS increased FBF from 2.60.3 to 5.81.1
mL · min1 · dL1. As illustrated in Figure 4B, quinine did not
change the norepinephrine sensitivity (PNS). In the tolbutamide
group, baseline FBF averaged 2.30.3 mL · min1 · dL1, which
increased to 6.41.1 mL · min1 · dL1 after the administration of
LPS. Intrabrachial infusion of the KATP blocker tolbutamide had no
effect on norepinephrine sensitivity (PNS; Figure 4C). Both
quinine and tolbutamide had no direct effect on FBF, blood
pressure, or heart rate (data not shown).
Administration of LPS increased FBF from 2.60.5 to
5.81.3 mL · min1 · dL1 in the TEA group. Intrabrachial
TABLE 1. Demographic Characteristics of the Study Groups.
Study Group LPS-Controls LPS-TEA LPS-Quinine LPS-Tolbutamide LPS–L-NMMA–TEA No LPS–L-NMMA–TEA
Sex, male/female 3/3 3/3 3/3 3/3 3/3 3/3
Age, y 232 234 222 211 212 201
Height, cm 1739 17310 17913 1777 1797 17310
Weight, kg 71.78.3 67.79.9 73.313.7 73.410.4 76.712.8 67.611.0
BMI, kg/m2 24.01.2 22.62.0 22.92.2 23.52.3 23.92.9 22.42.1
Systolic blood pressure, mm Hg 1298 12010 13016 13614 13712 11214*
Diastolic blood pressure, mm Hg 729 686 749 737 746 5911*
Heart rate, bpm 5710 5813 709 6010 628 7615
Forearm volume, mL 1067246 942258 992225 979158 1008267 858163
Total cholesterol, mmol/L 3.60.6 3.60.8 3.60.7 3.40.5 3.40.5 3.30.5
LDL cholesterol, mmol/L 2.100.47 2.180.75 2.210.47 2.060.51 2.070.60 1.990.47
HDL cholesterol, mmol/L 1.130.20 1.080.22 1.090.33 0.940.12 0.970.19 0.960.25
TG, mmol/L 0.800.51 0.740.27 0.730.20 0.840.44 0.780.16 0.790.39
BMI indicates body mass index; LDL, low-density lipoprotein; HDL, high-density lipoprotein; and TG, triglycerides. Blood pressure was measured intra-arterially;
heart rate was assessed by ECG. Data are meanSD.
*Apart from a significantly lower baseline blood pressure in the no LPS–L-NMMA–TEA group, there were no baseline imbalances between groups.
Figure 2. LPS-induced changes in cytokine
plasma concentrations. Administration of 2
ng/kg E coli LPS resulted in a marked
increase in tumor necrosis factor-, IL-6,
interferon-, and IL-10 concentrations. Data
are expressed as meanSEM (n18).
Changes in cytokine concentrations were all
significant (P0.0001) as analyzed with
repeated-measures ANOVA over the complete
curve. TNF indicates tumor necrosis factor;
INF-y, interferon-.
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administration of TEA at 4 hours after LPS administration did
not change the FBF in the infused arm (from 5.81.3 to
5.51.7 mL · min1 · dL1; PNS). Figure 5A shows the
potentiating effect of TEA on the LPS-impaired norepineph-
rine dose-response curve (P0.045, repeated-measures
ANOVA). Intrabrachial administration of TEA did not sig-
nificantly change the contralateral FBF (6.11.0 to 5.71.1
mL · min1 · dL1), blood pressure (1094/592 to 1065/
602 mm Hg), or heart rate (925 to 895 bpm).
Protocol 3: Effects of NO Synthase Inhibitor L-NMMA
and Coinfusion of K-Channel Blocker TEA on
Norepinephrine Sensitivity During Endotoxemia
Figure 5B shows the norepinephrine dose-response curve in
the presence of the NO synthase inhibitor L-NMMA. In this
group, FBF increased from 2.80.6 mL · min1 · dL1 at
baseline to 6.30.9 mL · min1 · dL1 after the administra-
tion of LPS. Intrabrachial administration of L-NMMA re-
duced FBF to 3.50.8 mL · min1 · dL1 (P0.005, paired t
test), with no significant changes in the contralateral arm
(6.21.1 to 5.81.2 mL · min1 · dL1), blood pressure
(1264/672 to 1232/681 mm Hg), or heart rate (924
to 884 bpm). L-NMMA significantly restored the attenu-
ated vasoconstrictor response to norepinephrine (P0.009,
repeated-measures ANOVA). The subsequent norepinephrine
dose-response curve in the presence of both L-NMMA and
TEA demonstrated that TEA does not exert an additional
potentiating effect in the presence of L-NMMA.
Protocol 4: Effect of K-Channel Blockers and NO
Inhibition on Norepinephrine Sensitivity in the
Absence of Endotoxemia
Norepinephrine (1 to 3 · min1 · dL1 to 10 to 30 ng · min1 ·
dL1) -induced vasoconstriction was 9811%, 8611%,
569%, and 315%. Intrabrachial infusion of TEA did not
change FBF (from 3.60.7 to 2.80.8 mL · min1 · dL1;
PNS) and did not alter the sensitivity to norepinephrine (in
the presence of TEA, 9211%, 10620%, 8614%, and
5215%; PNS) in the absence of endotoxemia.
Intrabrachial infusion of L-NMMA decreased FBF from
3.31.7 to 1.90.6 mL · min1 · dL1 (P0.01), with no
significant changes in the FBF of the control forearm, blood
pressure, and heart rate (data not shown). The norepineph-
TABLE 2. Pooled Data of Cardiovascular and Hemodynamic
Parameters of All LPS-Treated Subjects
Baseline 4 Hours After LPS P
HR, bpm 673 952 0.0001
SBP, mm Hg 1454 1223 0.0001
DBP, mm Hg 793 622 0.0001
FBF, mL · min1 · dL 2.90.3 7.00.6 0.0001
FVR, AU 39.03.5 13.31.2 0.0001
HR indicates heart rate; SBP, systolic blood pressure; DBP, diastolic blood
pressure; FVR, forearm vascular resistance; and AU, arbitrary units. Adminis-
tration of 2 ng/kg E coli LPS resulted in significant cardiovascular changes,
illustrating that LPS induces a vasodilatory state. Data are expressed as
mean SEM of 30 experiments. The probability values refer to the difference
between baseline and 4 hours after the administration of LPS as analyzed with
repeated-measures ANOVA over the complete curves (HR, SBP, DBP) or
Student t test for paired data (FBF and FVR). n30.
Figure 3. Dose-response curve of intrabrachial norepinephrine
(1 to 3 ng · min1 · dL1 to 10 to 30 ng · min1 · dL1) on FBF
before (open symbols, dotted line) and 4 hours after (solid sym-
bols) administration of 2 ng/kg E coli LPS. Percentages of base-
line FBF ratio (intervention/control arm) are presented as
meanSEM (n30). LPS significantly attenuated the vasocon-
strictor response to norepinephrine. The probability value refers
to the statistical difference between the dose-response curves
as analyzed with repeated-measures ANOVA.
Figure 4. A, Percentage decrease in the ratio of the FBF in the
infused and noninfused arms during graded intrabrachial norepi-
nephrine infusion (1 to 3 ng · min1 · dL1 to 10 to 30 ng · min1 ·
dL1) 4 hours after 2 ng/kg E coli LPS both in the absence (solid
symbols) and presence (5 hours; open symbols, dotted line) of
concomitant infusion of NaCl 0.9% (time controls, n6; PNS). B,
The same protocol, now in the absence (solid symbols) and pres-
ence (open symbols) of concomitant infusion of quinine (50
g · min1 · dL1; PNS). C, The same protocol, now in the
absence (solid symbols) and presence (open symbols) of concomi-
tant infusion of tolbutamide (1 mg · min1 · dL1; PNS). Data are
presented as meanSEM. The probability values refer to the sta-
tistical difference between the dose-response curves as analyzed
by repeated-measures ANOVA.
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rine-induced vasoconstriction in the presence of L-NMMA
also was not significantly different from the baseline dose-
response curve (in the presence of L-NMMA, 8414%,
569%, 5010%, and 3512%).
During the preparation of this manuscript, additional ex-
periments with LPS and TEA using the same protocol as in
the present study were conducted. In the group of 10 subjects,
the probability value of the TEA-mediated improvement of
the norepinephrine vasoconstriction was 0.015.
Discussion
Our study demonstrates that blockade of vascular K channels
or inhibition of NO synthase restores the attenuated vasopres-
sor effect of norepinephrine during human experimental
endotoxemia. Furthermore, K-channel blockade in the pres-
ence of the NO inhibitor L-NMMA did not further potentiate
the norepinephrine vasoconstrictive effects, suggesting that
the endotoxin-induced effect on K channels is mediated by
NO. Additional experiments with various K-channel blockers
indicate that the effects of endotoxin on the vasculature are
the result of NO-mediated opening of KCa channels.
Our findings on LPS-induced vasodilation and hyporeac-
tivity to norepinephrine confirm previous reports using the
human endotoxemia model.16,17 Pleiner et al16 demonstrated
that infusion of LPS produced a systemic hypotensive and
inflammatory reaction that was associated with a reduced
sensitivity to adrenoceptor agonists. However, this profound
reduction in adrenoceptor-mediated constriction was not as-
sociated with an altered effect of NO synthase inhibition
because local L-NMMA administration did not lead to a more
pronounced vasoconstriction during endotoxemia compared
with control circumstances. In the present study, we found
that intra-arterial administration of L-NMMA does potentiate
the vasopressor response to norepinephrine. This may suggest
that LPS-induced vasodilatation and the development of
hypotension/vasodilation on one hand and the induction of
vascular LPS-induced hyporeactivity to norepinephrine on
the other hand may reflect different mechanisms. Our obser-
vation that NO inhibition does not potentiate the vasocon-
strictor response to norepinephrine under control circum-
stances (in the absence of LPS) is consistent with a previous
report.24
Of course, this observed effect of L-NMMA does not
necessarily imply that NO synthase inhibition is beneficial in
septic patients. Although systemic treatment of patients with
septic shock resulted in a significant rise in blood pressure,6
this was unfortunately associated with an increase in mortal-
ity in a randomized clinical trial.25 Both the fact that
L-NMMA is a nonselective NO synthase inhibitor that blocks
inducible and endothelial NO synthase and the dosage of
L-NMMA used in that clinical trial may have accounted for
the observed detrimental effects.
K-Channel Activation During Inflammation
Persistent membrane hyperpolarization by K-channel activa-
tion appears to account for much of the observed vascular
hyporeactivity of septic shock.7,8 Charybdotoxin, a selective
blocker of KCa channels, restores LPS-induced vascular hy-
poreactivity in isolated blood vessels, whereas glibenclamide,
a selective antagonist of KATP channels, is not effective in
vitro.9,26 In contrast, KATP blockers increase blood pressure
during experimental septic shock in various in vivo animal
models.11,12 Thus, from animal experiments, there is good
evidence that K-channel blockers are beneficial in the treat-
ment of vasodilatory shock, leading to an increase in blood
pressure, an increase in vasopressor sensitivity, and even a
reduction in mortality.9–12 We have previously demonstrated
that vasodilation associated with pharmacological K-channel
activation by diazoxide is associated with a distinct blunting
of the vasoconstrictor response to norepinephrine in hu-
mans.22 In addition, we found that concurrent administration
of the K-channel blocker TEA could reduce the diazoxide-
mediated vasodilation, indicating that pharmacological mod-
ulation of vascular K channels may provide a novel treatment
opportunity.22 Nevertheless, until now, the role of K-channel
activation during systemic inflammation in humans was
unknown. Our results on the LPS-induced attenuated norepi-
nephrine sensitivity and its restoration by TEA in humans are
consistent with previous data showing full reversal of hyper-
polarization27 and hyporeactivity27,28 by TEA in isolated
vessels. Because TEA is a nonselective blocker of both KCa
and KATP channels, the experiments with TEA do not differ-
entiate between these 2 vascular K channels. Because the
selective KATP blocker tolbutamide showed no potentiating
effect, however, we have to conclude that vascular KCa
Figure 5. A, Percentage decrease in the ratio of the FBF in the
infused and noninfused arms during graded intrabrachial norepi-
nephrine infusion (1 to 3 ng · min1 · dL1 to 10 to 30 ng · min1
· dL1) 4 hours after 2 ng/kg E coli LPS both in the absence
(solid symbols) and presence (5 hours; open symbols, dotted
line) of concomitant infusion of TEA (1 mg · min1 · dL1; n6).
B, The same protocol, now in the absence (solid symbols) and
presence (open symbols) of concomitant infusion of L-NMMA
(0.2 mg · min1 · dL1; P0.009) or L-NMMATEA (open sym-
bols with dotted line; PNS vs L-NMMA alone; n6). Data are
presented as meanSEM. The probability values refer to the
statistical difference between the dose-response curves as ana-
lyzed by repeated-measures ANOVA.
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channels mediate the vascular hyporesponsiveness to norepi-
nephrine during human endotoxemia. This observation is in
accordance with various in vitro studies that demonstrate
involvement of the KCa channel, and not the KATP channel,
with the use of TEA8,9 or highly specific KCa channel blockers
like charybdotoxin8,9 and iberiotoxin.29 The absence of a
potentiating effect of quinine may well be explained by its
rather poor specificity because quinine also acts as an
-adrenergic blocking agent.30 The fact that the vasoconstric-
tor response to various agonists (norepinephrine, angiotensin
II, vasopressin) is attenuated during endotoxemia17 supports
the idea that the final common pathway is affected (influx of
calcium and an increase in intracellular calcium), and not the
specific receptors or specific signaling pathways for the
aforementioned vasoconstrictor substances. Thus, it is likely
that TEA also will improve the vasoconstrictor response to
angiotensin II and vasopressin because the action of these
agents is also dependent of calcium influx from voltage-
operated Ca channels, of which the open-state probability is
mediated predominantly by K channels. Moreover, our con-
trol experiments performed in subjects who did not receive
LPS demonstrate that TEA does not potentiate the norepi-
nephrine response in the absence of systemic inflammation,
indicating that the potentiating effect of TEA is not due to a
direct interaction with the vascular -receptor.
The intracellular signaling by which K channels are acti-
vated during human endotoxemia is largely unknown. Be-
cause K-channel blockade with TEA did not exert an addi-
tional effect during NO synthase inhibition, NO may be
responsible for the activation of the vascular K channels.
Interestingly, apart from direct activation by high concentra-
tions of LPS,31 patch-clamp experiments have shown that NO
can directly13 and indirectly (through guanylate cyclase)14
activate single vascular KCa channels. The NO-mediated
pathway appears plausible because LPS is cleared from the
bloodstream within 20 minutes during experimental human
endotoxemia and because cytokines do not activate vascular
K channels or directly dilate human vessels.32
Recently, Singer and colleagues33 reported that life-
threatening complications related to K-channel– opening
drugs subsided after the administration of the K-channel
blocker glibenclamide. Glibenclamide appeared to be effec-
tive in several cases, but not in septic shock. Our data confirm
this observation of Singer et al that selective KATP blockade
with sulfonylurea derivatives (tolbutamide, glibenclamide)
may not be helpful in the hemodynamic management of
septic shock. According to our data, other K-channel blockers
like TEA may be more effective.
Therapeutic Implications
In the past, TEA was used as an antihypertensive drug
because of its ganglion-blocking properties.34 This effect is
not confounding the data in the present study because we
infused the drug into the brachial artery, distal of the
sympathetic ganglia. On the basis of its ganglion-blocking
properties, systemic administration of TEA may have a blood
pressure–lowering effect in septic patients with an activated
sympathetic system, which may limit its use in this specific
group of patients. However, systemic administration of TEA
in normotensive patients did not lower blood pressure.35 In
experimental animals, systemic treatment with TEA during
endotoxic shock in rats did not deteriorate the LPS-induced
fall in blood pressure,36 and intravenously administered TEA
fully restored the responsiveness to phenylephrine in rats
injected with LPS.37 Although the data are limited, these
results are encouraging and suggest that TEA may represent
a possible future therapeutic opportunity to modulate vascular
tone in septic shock patients. The next step to explore the
potential therapeutic properties of K-channel blockers in
vasodilatory shock would be systemic administration of TEA
during experimental endotoxemia or in septic patients.
Conclusions
Our experiments indicate that NO-mediated activation of KCa
channels is responsible for the observed hyporeactivity to
norepinephrine during human endotoxemia and confirm in
vitro and animal data that pharmacological inhibition of
vascular K channels restores the attenuated norepinephrine
sensitivity during systemic inflammation. Pharmacological
modulation of vascular K channels represents a novel treat-
ment modality for septic shock.
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CLINICAL PERSPECTIVE
Worldwide, an estimated 6 million patients die of sepsis each year. Vasodilatory shock, characterized by systemic
vasodilatation and an attenuated sensitivity to vasopressor therapy with norepinephrine, is the main cause of mortality
during sepsis. Recent research indicates that the attenuated response to norepinephrine is caused by activation of vascular
potassium (K) channels. The opening of these channels, triggered by inflammation and induction of nitric oxide,
hyperpolarizes the vascular smooth muscle cell, leading to closure of voltage-operated calcium channels and a decrease in
intracellular calcium. Consequently, the decreased intracellular calcium concentration results in an attenuated norepineph-
rine-induced smooth muscle contraction and vasoconstrictor response. This pathophysiological mechanism has been widely
examined in various animal and in vitro models of inflammation, whereas human data are lacking. The present study
demonstrates that administration of Escherichia coli lipopolysaccharide to healthy human volunteers induces a systemic
inflammatory response, leading to a blunted vasoconstrictive response to norepinephrine in the human forearm vasculature.
More importantly, it is demonstrated that coinfusion of the K-channel blocker tetraethylammonium completely restores the
attenuated response to norepinephrine during systemic inflammation. This implies that in humans vascular K-channel
activation plays a pivotal role in the reduced vasoconstrictor response to norepinephrine during systemic inflammation.
Consequently, K-channel blockade could be a novel method to reduce sepsis-induced vasorelaxation and to improve the
response to vasopressor therapy with norepinephrine. This finding warrants additional research into vascular K-channel
blockade in septic patients to improve the management of hemodynamic instability in this group of patients.
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